CDC Releases Infection Prevention Guide to Promote Safe Outpatient Care

abstract: Symptom burden in cancer survivors 1 year after diagnosis Cancer

CONCLUSIONS:

More than 1 in 4 cancer survivors had high symptom burden 1 year postdiagnosis, even after treatment termination. These results indicate a need for continued symptom monitoring and management in early post-treatment survivorship, especially for the underserved.

Apr 2011: free full access - Recognition and initial management of ovarian cancer: summary of NICE guidance -- bmj.com

Note: guidelines include Carboplatin alone in high-risk early stage; IP for advanced stage ovarian cancer via clinical trial/s (which brings up the question as to the availability of trials??) Future research What is the relationship between the duration and frequency of symptoms in women with ovarian cancer before diagnosis, and the stage of disease at diagnosis and subsequent survival? What is the optimum threshold on the risk of malignancy index I (RMI I) that should be applied in secondary care to guide the management of women with suspected ovarian cancer? How does computed tomography compare with magnetic resonance imaging in accuracy of staging and prediction of optimal cytoreduction? Answering this will require large, multicentre case-control studies. What are the cost effectiveness and risks of systematic retroperitoneal lymphadenectomy in women whose ovarian cancer seems to be confined to the ovaries? Answering this will require a prospective randomised trial. What is the effectiveness of primary surgery in women with advanced ovarian cancer that cannot be fully excised?

Test Results Management (Canadian Patient Safety/College of Physicians & Surgeons Ontario)

full free access: Self-management: Enabling and empowering patients living with cancer as a chronic illness Cancer Jnl

National Guideline Clearinghouse | New This Week focus on breast cancer (New Zealand)

New Zealand Guidelines Group

-

General principles of care. In: Management of early breast cancer.

-

Staging. In: Management of early breast cancer.

-

Surgery for early invasive breast cancer. In: Management of early breast cancer.

-

Radiotherapy. In: Management of early breast cancer.

-

Systemic therapy: chemotherapy regimens. In: Management of early breast cancer.

-

Systemic therapy: endocrine therapies. In: Management of early breast cancer.

-

Ductal carcinoma in situ. In: Management of early breast cancer.

-

Follow-up. In: Management of early breast cancer.

-

Special issues. In: Management of early breast cancer.

abstract: Clinical aspects of the management of elderly women diagnosed with gynecologic malignancies: Treatment decisions and choices

Management of Asymptomatic Ovarian and Other Adnexal Cysts Imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement1 — Radiology

Note: excellent detailed paper

Chemotherapy Options in the Management of Platinum-Sensitive Recurrent Ovarian Cancer

Note: registration required to view (free) SPECIAL EDITION / EDUCATIONAL REVIEWS

ISSUE: AUGUST, 2010 | VOLUME: 05:08 Chemotherapy Options in the Management of Platinum-Sensitive Recurrent Ovarian Cancer

full free access: Clinical Care Options Oncology - Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer (slides)

>

Clinical Management of Borderline Tumours of the Ovary – Experience from the “Berlin Online Tumour Conference for Gynaecological Malignancies” — Anticancer Research

Abstract

Borderline ovarian tumour (BOT) represents a rare and special tumour entity. Despite a generally favourable prognosis for patients with BOT, the presence of invasive peritoneal implants decreases the survival rate to 30-50%. In contrast to ovarian cancer, only few data exist concerning the current clinical management of patients with BOT. For this reason, the present analyses were performed for patients with BOT who were admitted into our online tumor conference for patients with gynaecological malignancies. Based on the results discussed in this article, the current aspects and problems regarding the diagnostic, surgical and conservative treatment and aftercare management of patients with BOT are considered.

Cardiovascular Safety of VEGF-Targeting Therapies: Current Evidence and Handling Strategies -- Girardi et al., 10.1634/theoncologist.2009-0235 -- The Oncologist

Abstract
Treatment with the angiogenesis inhibitors bevacizumab, sunitinib, and sorafenib as single agents or in combination with conventional chemotherapy is becoming a cornerstone of modern anticancer therapy. However, the potential toxicity of these drugs, mainly to the cardiovascular system, is still being investigated. Patient assessment at baseline, of crucial importance in candidates for treatment, involves the evaluation of risk factors and screening for past or present cardiovascular disease. Strict monitoring of treatment-related adverse effects must be conducted in order to allow the early detection of cardiovascular toxicities and their prompt medication. In the present paper, the most frequent cardiovascular toxicities and their underlying mechanisms are investigated, with a view to providing indications for effective patient management.

2010 Institute for Continuing Healthcare Education - Ovarian Cancer Screening and Management to Improve Patient Survival

OVERVIEW

Ovarian cancer is the leading cause of death from gynecologic malignancy and the fifth leading cause of cancer‐related death among women in the United States. The high mortality rate associated with ovarian cancer is due in part to the lack of effective screening strategies to detect the disease in early stages (I or II) when the cancer is confined to the ovary. Since symptoms associated with ovarian cancer are typically nonspecific, a clinical diagnosis is difficult to make until the disease has advanced. The Institute for Continuing Healthcare Education has identified a number of areas related to the screening, diagnosis, and treatment of ovarian cancer where education is vital in order to address the need for improvement in professional care.

PROGRAM DESCRIPTION

In this Webcast, the faculty members will present up-to-date, relevant information on screening guidelines, referral procedures, and therapies for ovarian cancer. As a learning reinforcement, individuals who complete this activity will be able to request a certified monograph with two case studies pertaining to the treatment strategies discussed within the Webcast.

INSTRUCTIONS FOR OBTAINING CME/CE CREDIT

There are no fees or prerequisites for participating in and receiving CME/CE credit for this online educational activity.

Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma

Note: this issue is important as early-age diagnoses in Lynch Syndrome is common

"Approximately one quarter of women diagnosed with Lynch syndrome-associated CRC (colorectal cancer) developed EC within 10 years. This supports the sentinel cancer concept and suggests that active and early management is important for these women."

How Does Older Age Influence Oncologists' Cancer Management? - The Oncologist

Reference to ovarian cancer:
10.  Eisenhauer EL, Tew WP, Levine DA et al. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane
chemotherapy. Gynecol Oncol 2007;106:381–387.

Clinical relevance of rare germline sequence variants in cancer genes

Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models.

Abstract

Multifactorial models developed for BRCA1/2 variant classification have proved very useful for delineating BRCA1/2 variants associated with very high risk of cancer, or with little clinical significance. Recent linkage of this quantitative assessment of risk to clinical management guidelines has provided a basis to standardize variant reporting, variant classification and management of families with such variants, and can theoretically be applied to any disease gene. As proof of principle, the multifactorial approach already shows great promise for application to the evaluation of mismatch repair gene variants identified in families with suspected Lynch syndrome. However there is need to be cautious of the noted limitations and caveats of the current model, some of which may be exacerbated by differences in ascertainment and biological pathways to disease for different cancer syndromes.

Anti-angiogenesis therapies: their potential in cancer management

Note: click on 'pdf' for (free) access to the full paper

Clinical Update - Ovarian Cancer (commentary - Australia)- Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer ...

Note: abstract plus commentary from Australian specialist/Associate Professor Jim Nicklin; includes reference to upcoming trial results

Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal

Emerging role of radiotherapy in the management of liver metastases